Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 12,548 matching trials from the live ClinicalTrials.gov search.

Filters: Miami, Florida Clear all

Conditions: Type 2 Diabetes Mellitus
Interventions: Autologous stem cells, Hyperbaric oxygen therapy, Insulin, Metformin; Biological · Other · Drug
Lead sponsor: Rodolfo Alejandro; Other
Eligibility: 45 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Crohn's Disease
Interventions: Trichuris suis ova (TSO), Placebo; Biological
Lead sponsor: Coronado Biosciences, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 73
States / cities: Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 64 more

Conditions: Cystic Fibrosis, Colorectal Cancer, Adenoma
Interventions: Stool tests; Procedure
Lead sponsor: University of Washington, the Collaborative Health Studies Coordinating Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 26
States / cities: Los Angeles, California • Palo Alto, California • Denver, Colorado + 21 more

Conditions: Cervical Dystonia
Interventions: Botulinum toxin type A; Biological
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 14
States / cities: Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 10 more

Conditions: Alpha1-Antitrypsin Deficiency
Interventions: Alpha-1 15%, Liquid Alpha1-Proteinase Inhibitor (Human); Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Gainesville, Florida • Miami, Florida + 2 more

Conditions: Epilepsies, Myoclonic, Drug Resistant Epilepsy
Interventions: Lorcaserin; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 2 Years and older
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 14 more

Conditions: Alzheimer's Disease
Interventions: Not listed
Lead sponsor: AstraZeneca; Industry
Eligibility: Not listed
Enrollment: 2,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 48
States / cities: Northport, Alabama • Phoenix, Arizona • Brentwood, California + 45 more

Conditions: Hepatic Insufficiency
Interventions: Elbasvir; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Hepatitis B
Interventions: Entecavir (ETV), Adefovir (ADV); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 16 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 16
States / cities: San Diego, California • San Francisco, California • New Haven, Connecticut + 11 more

Conditions: Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
Interventions: Carboplatin, Laboratory Biomarker Analysis, Metformin Hydrochloride, Paclitaxel, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 431
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 298 more

Conditions: Metastatic Breast Cancer
Interventions: Palbociclib, Fulvestrant, Avelumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 22
States / cities: Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 18 more

Conditions: Laryngeal Cancer, Laryngectomy
Interventions: SpeakFree HME Hands Free Valve, Digital Occlusion, Digital Depression HME; Device · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Prostate Cancer, Prostate Cancer (Adenocarcinoma), Fluorescence Imaging
Interventions: AS1986NS; Drug
Lead sponsor: Antelope Surgical Solutions, Inc; Industry
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Miami, Florida • New York, New York

Conditions: Type 2 Diabetes Mellitus
Interventions: Placebo, Dulaglutide, Glimepiride; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 6
States / cities: Chino, California • Miami, Florida • St Louis, Missouri + 3 more

Conditions: Crohn's Disease, Ulcerative Colitis
Interventions: 25 mg Ontamalimab, 75 mg Ontamalimab; Drug
Lead sponsor: Shire; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 557 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 103
States / cities: Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 88 more

Conditions: Healthy Participants
Interventions: BMS-986278, Sildenafil, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 35 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 2
States / cities: Cypress, California • Miami, Florida

Conditions: Schizophrenia
Interventions: Abilify MyCite®; Combination Product
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 68
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 55 more

Conditions: Stroke
Interventions: Amulet Left Atrial Appendage Occluder, WATCHMAN Left Atrial Appendage Closure; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 1,878 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 85
States / cities: Huntsville, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 70 more

Conditions: Glabellar Lines
Interventions: AGN-151586, Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Fremont, California • Santa Monica, California • Miami, Florida + 6 more

Conditions: HIV Infections, Tuberculosis
Interventions: Isoniazid, Pyridoxine hydrochloride, Levofloxacin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Torrance, California + 7 more

Conditions: Non-small Cell Lung Cancer
Interventions: Pembrolizumab, Placebo, Cisplatin, Gemcitabine, Pemetrexed; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 797 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 51
States / cities: Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 45 more

Conditions: Wheezing, Asthma
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 14
States / cities: Phoenix, Arizona • Destin, Florida • Miami, Florida + 11 more

Conditions: Breast Cancer, Breast Neoplasms, Breast Diseases
Interventions: Biospecimen Collection, Surgical Tissue Collection, Survey Collection; Other · Diagnostic Test · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Los Angeles, California • Miami, Florida • New York, New York

Conditions: Narcolepsy, Cataplexy Narcolepsy, Excessive Sleepiness
Interventions: AXS-12 (Reboxetine), Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 14
States / cities: Birmingham, Alabama • Alameda, California • Santa Ana, California + 11 more

Search by objective public record fields.

Autologous Stem Cell and Hyperbaric Oxygen Therapy in Type 2 Diabetes Mellitus

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Colorectal Cancer Screening in Cystic Fibrosis

Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies

Observational Study on Costs and Caregiver Burden in Alzheimer's Disease

The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009)

Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation

Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer

Palbociclib After CDK and Endocrine Therapy (PACE)

SpeakFree Heat and Moisture Exchanger (HME)

A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS

Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)

A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®

AMPLATZER™ Amulet™ LAA Occluder Trial

AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines

A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)

A Study of Breast Cancer Risk Factors and Outcomes of People in Florida

Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)